The burgeoning popularity of retatrutide, initially for blood sugar control , is creating significant buzz within the UK , prompting a notable shift in peptide trends. Access these compounds remains a complex landscape, with NHS coverage currently limited and private clinics offering prescriptions at a higher cost . Concerns are being raised regard